These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 30165166)

  • 1. TERT promoter mutations are associated with poor prognosis in cutaneous squamous cell carcinoma.
    Campos MA; Macedo S; Fernandes M; Pestana A; Pardal J; Batista R; Vinagre J; Sanches A; Baptista A; Lopes JM; Soares P
    J Am Acad Dermatol; 2019 Mar; 80(3):660-669.e6. PubMed ID: 30165166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Significance of RAS Mutations and P53 Expression in Cutaneous Squamous Cell Carcinomas.
    Campos MA; Macedo S; Fernandes MS; Pestana A; Pardal J; Batista R; Vinagre J; Sanches A; Baptista A; Lopes JM; Soares P
    Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32640663
    [No Abstract]   [Full Text] [Related]  

  • 3. Telomeres and Telomerase in Cutaneous Squamous Cell Carcinoma.
    Ventura A; Pellegrini C; Cardelli L; Rocco T; Ciciarelli V; Peris K; Fargnoli MC
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30884806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas.
    Nencha U; Rahimian A; Giry M; Sechi A; Mokhtari K; Polivka M; Schmitt Y; Di Stefano AL; Alentorn A; Labussière M; Sanson M
    J Neurooncol; 2016 Feb; 126(3):441-6. PubMed ID: 26608520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TERT promoter mutations in penile squamous cell carcinoma: high frequency in non-HPV-related type and association with favorable clinicopathologic features.
    Kim SK; Kim JH; Han JH; Cho NH; Kim SJ; Kim SI; Choo SH; Kim JS; Park B; Kwon JE
    J Cancer Res Clin Oncol; 2021 Apr; 147(4):1125-1135. PubMed ID: 33635430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism.
    Batista R; Cruvinel-Carloni A; Vinagre J; Peixoto J; Catarino TA; Campanella NC; Menezes W; Becker AP; de Almeida GC; Matsushita MM; Clara C; Neder L; Viana-Pereira M; Honavar M; Castro L; Lopes JM; Carvalho B; Vaz RM; Máximo V; Soares P; Sobrinho-Simões M; Reis RM; Lima J
    Int J Cancer; 2016 Jul; 139(2):414-23. PubMed ID: 26914704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TERT Promoter Mutational Status in the Management of Cutaneous Melanoma: Comparison with Sentinel Lymph Node Biopsy.
    Martins F; Martins C; Fernandes MS; Andrade MI; Lopes JM; Soares P; Pópulo H
    Dermatology; 2022; 238(3):507-516. PubMed ID: 34569488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telomerase reverse transcriptase promoter mutations and solar elastosis in cutaneous melanoma.
    Lade-Keller J; Yuusufi S; Riber-Hansen R; Steiniche T; Stougaard M
    Melanoma Res; 2018 Oct; 28(5):398-409. PubMed ID: 29570169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: A systematic review and meta-analysis.
    Chen B; Shi Y; Xu Y; Zhang J
    Clin Endocrinol (Oxf); 2021 May; 94(5):731-742. PubMed ID: 32816325
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Batista R; Lima L; Vinagre J; Pinto V; Lyra J; Máximo V; Santos L; Soares P
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32023888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological and Prognostic Values of Telomerase Reverse Transcriptase (
    Yoo H; Kim HS
    Cancer Genomics Proteomics; 2023; 20(6):626-636. PubMed ID: 37889060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer.
    Leão R; Lee D; Figueiredo A; Hermanns T; Wild P; Komosa M; Lau I; Mistry M; Nunes NM; Price AJ; Zhang C; Lipman T; Poyet C; Valtcheva N; Oehl K; Coelho H; Sayyid R; Gomes AM; Prado E Castro L; Sweet J; Vinagre J; Apolónio J; Stephens D; Faleiro I; Fadaak K; Richard PO; Kulkarni G; Zlotta AR; Hamilton RJ; Castelo-Branco P; Tabori U
    Int J Cancer; 2019 Apr; 144(7):1676-1684. PubMed ID: 30350309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TERTp mutation is associated with a shorter progression free survival in patients with aggressive histology subtypes of follicular-cell derived thyroid carcinoma.
    Penna GC; Pestana A; Cameselle JM; Momesso D; de Andrade FA; Vidal APA; Araujo Junior ML; Melo M; Fernandes PV; Corbo R; Vaisman M; Sobrinho-Simões M; Soares P; Vaisman F
    Endocrine; 2018 Sep; 61(3):489-498. PubMed ID: 29948935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coexistence of
    Rusinek D; Pfeifer A; Krajewska J; Oczko-Wojciechowska M; Handkiewicz-Junak D; Pawlaczek A; Zebracka-Gala J; Kowalska M; Cyplinska R; Zembala-Nozynska E; Chekan M; Chmielik E; Kropinska A; Lamch R; Jurecka-Lubieniecka B; Jarzab B; Czarniecka A
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30200646
    [No Abstract]   [Full Text] [Related]  

  • 16. TERT promoter mutations in periocular carcinomas: implications of ultraviolet light in pathogenesis.
    Lin SY; Liao SL; Hong JB; Chu CY; Sheen YS; Jhuang JY; Tsai JH; Liau JY
    Br J Ophthalmol; 2016 Feb; 100(2):274-7. PubMed ID: 26472403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline.
    Sun ZL; Chan AK; Chen LC; Tang C; Zhang ZY; Ding XJ; Wang Y; Sun CR; Ng HK; Yao Y; Zhou LF
    Int J Clin Exp Pathol; 2015; 8(9):11485-94. PubMed ID: 26617880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TERT promoter mutations in primary and secondary WHO grade III meningioma.
    Maier AD; Stenman A; Svahn F; Mirian C; Bartek J; Juhler M; Zedenius J; Broholm H; Mathiesen T
    Brain Pathol; 2021 Jan; 31(1):61-69. PubMed ID: 32805769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic significance of TERT promoter mutations in meningioma: a systematic review and meta-analysis.
    Lu VM; Goyal A; Lee A; Jentoft M; Quinones-Hinojosa A; Chaichana KL
    J Neurooncol; 2019 Mar; 142(1):1-10. PubMed ID: 30506498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TERT promoter mutation in sebaceous neoplasms.
    Muñoz-Jiménez MT; Blanco L; Ruano Y; Carrillo R; Santos-Briz Á; Riveiro-Falkenbach E; Requena L; Kutzner H; Garrido MC; Rodríguez-Peralto JL
    Virchows Arch; 2021 Sep; 479(3):551-558. PubMed ID: 33768319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.